GIST pipeline
Trial arms side by side.
One row is one arm. A blank cell is n/r. A hazard ratio appears only when the source states it. Weeks stay weeks, and a patient count stays a count.
ClassNone selected
No arms selected. Choose a drug, an arm, or a preset.
26 of 32 arms with a reported figure. Choose arms to narrow the chart.
months 21
Imatinib 400 mg. median progression-free survival: 18.9 months, median follow up 37.5 months
Imatinib 800 mg. median progression-free survival: 23.2 months, median follow up 37.5 months
Regorafenib 160 mg. median progression-free survival: 4.8 months, primary analysis
Regorafenib placebo. median progression-free survival: 0.9 months, primary analysis
Ripretinib 150 mg. median progression-free survival (BICR): 6.3 months, primary analysis
Ripretinib placebo. median progression-free survival (BICR): 1 months, primary analysis
Ripretinib 150 mg. median progression-free survival (IRR), ITT: 8 months, primary analysis
Ripretinib 150 mg. median progression-free survival, KIT exon 11 ITT: 8.3 months, primary analysis
Ripretinib 150 mg. median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 14.2 months, exploratory, Exploratory ctDNA analysis (Heinrich, Nat Med 2024); nominal P
Ripretinib 50 mg. median progression-free survival (IRR), ITT: 8.3 months, primary analysis
Ripretinib 50 mg. median progression-free survival, KIT exon 11 ITT: 7 months, primary analysis
Ripretinib 50 mg. median PFS, exploratory ctDNA KIT exon 11 + 17/18 only: 1.5 months, exploratory
Ripretinib 50 mg. median PFS, exploratory ctDNA KIT exon 11 + 13/14 (sunitinib vs ripretinib 4.0): 15 months, exploratory
Avapritinib 300 mg. median progression-free survival: 4.2 months, primary analysis
Avapritinib 160 mg. median progression-free survival: 5.6 months, primary analysis
Bezuclastinib + Sunitinib 600 mg + 37.5 mg. median progression-free survival (BICR): 16.5 months, data cutoff 09.30.2025
Bezuclastinib + Sunitinib 37.5 mg. median progression-free survival (BICR): 9.2 months, data cutoff 09.30.2025
Velzatinib (IDRX-42, GSK6042981) 300 mg. median progression-free survival: 13.7 months, median follow up 14.7 months; cutoff 12.15.2025
Olverembatinib (HQP1351) 30 to 50 mg. median progression-free survival: 25.7 months, cutoff 11.13.2025
NB003 not stated in source. median progression-free survival: 9.2 months, data as of March 2025
NB003 not stated in source. median progression-free survival: 13.7 months, data as of March 2025
Bars in this group share the unit months. 25.7 months is the longest reported value here. A different unit is not redrawn onto this scale.
weeks 4
Sunitinib 50 mg. median time to tumor progression: 27.3 weeks, interim analysis
Sunitinib 50 mg. median progression-free survival: 24.1 weeks, interim analysis
Sunitinib placebo. median time to tumor progression: 6.4 weeks, interim analysis
Sunitinib placebo. median progression-free survival: 6 weeks, interim analysis
Bars in this group share the unit weeks. 27.3 weeks is the longest reported value here. A different unit is not redrawn onto this scale.
A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.